Earl Martin Douglas net worth and biography

Earl Douglas Biography and Net Worth

Earl Douglas is the General Counsel and Compliance Officer of Allogene. Earl has over 35 years of experience as an attorney, serving as legal counsel for publicly traded biotech and medical device companies as well as start-ups. In these roles, Earl advised management and boards on a wide range of legal and strategic matters, including corporate governance, SEC filings, commercial transactions, intellectual property strategy, mergers and acquisitions, corporate finance, litigation, and compliance programs. Most recently, Earl served as General Counsel of Applied Molecular Transport. Prior to that role, he served in the same capacity for Kiverdi. He has also served as General Counsel and Corporate Secretary at BioMimetic Therapeutics (acquired by Wright Medical Group), Spinal Dynamics (acquired by Medtronic), and OPX Biotechnologies (acquired by Cargill). He previously served as Counsel with Wilson Sonsini Goodrich & Rosati, and earlier in his career practiced as an Associate with Weil, Gotshal & Manges. Earl holds a J.D. from Columbia University School of Law and a B.S. in chemical engineering from the Massachusetts Institute of Technology (MIT).

What is Earl Martin Douglas' net worth?: The estimated net worth of Earl Martin Douglas is at least $846.50 thousand as of February 3rd, 2025. Mr. Douglas owns 587,848 shares of Allogene Therapeutics stock worth more than $846,501 as of December 5th. This net worth estimate does not reflect any other investments that Mr. Douglas may own. Learn More about Earl Martin Douglas' net worth.
How old is Earl Martin Douglas?: Mr. Douglas is currently 61 years old. There are 8 older executives and no younger executives at Allogene Therapeutics. The oldest executive at Allogene Therapeutics is Dr. Arie S. Belldegrun F.A.C.S., M.D., Co-Founder & Executive Chairman, who is 75 years old. Learn More on Earl Martin Douglas' age.
How do I contact Earl Martin Douglas?: The corporate mailing address for Mr. Douglas and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]. Learn More on Earl Martin Douglas' contact information.
Has Earl Martin Douglas been buying or selling shares of Allogene Therapeutics?: Earl Martin Douglas has not been actively trading shares of Allogene Therapeutics during the past quarter. Most recently, Earl Martin Douglas sold 6,404 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a transaction totalling $10,950.84. Following the completion of the sale, the senior vice president now directly owns 587,848 shares of the company's stock, valued at $1,005,220.08. Learn More on Earl Martin Douglas' trading history.
Who are Allogene Therapeutics' active insiders?: Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Arie Belldegrun (Director), Veer Bhavnagri (General Counsel), David Chang (President, Chief Executive Officer and Co-Founder), Earl Douglas (SVP), Franz Humer (Director), Stephen Mayo (Director), Geoffrey Parker (Executive Vice President, Chief Financial Officer), Zachary Roberts (Executive Vice President, Research & Development, Chief Medical Officer), Owen Witte (Director), and Annie Yoshiyama (SVP). Learn More on Allogene Therapeutics' active insiders.
Are insiders buying or selling shares of Allogene Therapeutics?: During the last year, insiders at the sold shares 10 times. They sold a total of 169,568 shares worth more than $294,129.46. The most recent insider tranaction occured on October, 21st when CFO Geoffrey M Parker sold 36,744 shares worth more than $46,297.44. Insiders at Allogene Therapeutics own 13.2% of the company. Learn More about insider trades at Allogene Therapeutics.
Information on this page was last updated on 10/21/2025.

Earl Martin Douglas Insider Trading History at Allogene Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/3/2025	Sell	6,404	$1.71	$10,950.84	587,848

Earl Martin Douglas Buying and Selling Activity at Allogene Therapeutics

Allogene Therapeutics Company Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.44

$1.41

$1.51

50 Day Range

MA: $1.28

$1.05

$1.52

2 Week Range

Now: $1.44

$0.86

$3.78

Volume

1,536,230 shs

Average Volume

2,359,507 shs

Market Capitalization

$323.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Earl Douglas Biography and Net Worth

What is Earl Martin Douglas' net worth?

How old is Earl Martin Douglas?

How do I contact Earl Martin Douglas?

Has Earl Martin Douglas been buying or selling shares of Allogene Therapeutics?

Who are Allogene Therapeutics' active insiders?

Are insiders buying or selling shares of Allogene Therapeutics?